Cutting-Edge Technology and Mitochondrial Diseases - Where is the Limit?
By Dusko Ilic,
BioNews
| 07. 27. 2015
Untitled Document
In their latest study, published in the Nature, Shoukrat Mitalipov and collaborators, including Juan Carlos Izpisua Belmonte, reported on two potential 'gene correction' strategies that can help patients with mitochondrial diseases (1, BioNews 811). Both approaches are built on the idea of mitochondria segregation phenomenon, reported for the first time by a group from the Mayo clinic in Rochester, Minnesota(2).
Basically, in proliferating cells the mitochondria segregate spontaneously and, if we start with a heteroplasmic cell containing a mix of healthy, wild-type and mutation-carrying mitochondria, after multiple cell divisions daughter cells will segregate into three major groups. The first will contain predominantly healthy, wild-type mitochondria with a few-to-nil mitochondria that carry the mutation, while the second is quite opposite – a vast majority of mitochondria will be carrying the deleterious mutation and almost none will be healthy. The third group will be heteroplasmic, containing various degrees of mixed normal and mutation-carrying mitochondria.
Read more...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...